# of Displayed Technologies: 10 / 50

Applied Category Filter (Click To Remove): Therapeutics


Categories

mRNA sequence engineering and uses thereof
TS-045448 — mRNA-based therapy applications
Many diseases emerge from irregularities that occur during protein synthesis. While limited therapies exist to deliver mature proteins to compensate for these errors, protein therapy by direct protein delivery has limited efficiency. This is due to difficulty in controlling the volume of delivered…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Zeng, Chunxi
  • Licensing Officer: Dahlman, Jason "Jay"

Improving immunotherapy with mRNA delivery
TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Li, Wenqing; Zhang, Chengxiang
  • Licensing Officer: Dahlman, Jason "Jay"

Nanoparticle Composition for Nucleic Acid Delivery
TS-044109 — Lipid nanoparticles (LNs) usable for the delivery of therapeutic compositions, including, but not limited to nucleic acids (NAs).
Nucleic Acid (NA) based therapies are used to inhibit gene expression. Lipid nanoparticles (LNs) are capable of carrying these therapies into cells. However, this delivery requires overcoming several physiological barriers. For instance, one barrier is the acidic endosome conditions within the cel…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: Dahlman, Jason "Jay"

Engineered Cells for Treatment of Animal Metabolic Disorders
TS-041976 — The implantation of engineered thermogenic cells for treating metabolic disease and obesity in animals.
Obesity remains one of the main underlying causes for many malignancies in domestic animals such as cats, dogs, and horses. From a veterinary perspective, obesity dramatically increases the risk of cancer, one of the leading causes of death in domesticated animals. Other diseases correlated with o…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana
  • Licensing Officer: Flammang, Ann Marie

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Cripe, Timothy; Kudryashova, Elena; Purde, Vedud
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Treatment of Multiple Sclerosis with small molecule IL-6/STAT3 inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Flammang, Ann Marie

Methods for generation of TF-targeting chimeric antigen receptors (CARs)-natural killer cells and T cells
TS-038262 — A therapeutic application of neovascular-targeting chimeric antigen receptor (CAR) T cells and NK cells for treating diseases associated with pathological angiogenesis, in which TF is abarrently expressed, such as solid tumors, leukemia, lymphoma, age-related macular degeneration (AMD), endometriosis, and rheumatoid arthritis.
Nearly 2,000,000 new cancer cases are expected to be diagnosed each year in the United States. Available treatment options include surgery, radiation therapy, chemotherapy, and immunotherapy. Recently, cell-based immunotherapy utilizing specific chimeric antigen receptor (CAR) expressing immune ce…
  • College: College of Medicine (COM)
  • Inventors: Hu, Zhiwei
  • Licensing Officer: Flammang, Ann Marie

A novel STK1-targeted small molecule as an "antibiotic resistance breaker"
TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.
Highly pathogenic and multidrug-resistant Staphylococcus aureus (MDRSA) encompasses methicillin-resistant strains of S. aureus that have developed resistance to multiple traditional antibiotics. Because of the recent emergence of antimicrobial resistance, MDRSA has been commonly incriminated in a …
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Davis, Stewart

Show More Technologies

Loading icon